Avid Bioservices, Inc.

Avid Bioservices, Inc.

CDMO
Avid Bioservices, Inc.US flagNASDAQ Capital Market
12.49
USD
- -
- -
-2.41EPS
-5.18P/E
798.90MMarket Cap
Apr 22Next Earn
Capital Structure

in mil. unless spec.
Working Capital

in mil. unless spec.
Growth Rates

in mil. unless spec.
Quarterly Revenue

in mil. unless spec.
Quarterly Earnings Per Share

in mil. unless spec.
Quarterly Dividends Per Share

in mil. unless spec.

Company Description

CEO
Mr. Nicholas Stewart Green B.Sc., MBA
Full Time Employees
371
Sector
Healthcare
Industry
Biotechnology
Address
2642 Michelle Drive Tustin CA United States of America 92780
IPO Date
Apr 4, 1994
Similar Companies
Business
Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. The company produces monoclonal antibodies and recombinant proteins; and offers services, including CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support. It also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, testing, and characterization. The company serves biotechnology and biopharmaceutical industries. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is headquartered in Tustin, California.

Company News

  • Tufts Center Study Shows Significant Time Savings in Delivering Therapies to Patients with Thermo Fisher Scientific's Accelerator™ Drug Development 360° CDMO and CRO Solutions

  • Scinai Highlights New Funding and CDMO Growth Ahead of BIO International Convention 2025

  • Frédéric Robert appointed EUROAPI's Chief Commercial Officer overseeing API Solutions and CDMO activities

  • Scinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash Burn

  • BioHarvest Secures New CDMO Contract to Develop Plant-based Fragrance Compound

  • BioHarvest Sciences advances CDMO deal with major pharmaceutical company - ICYMI

  • BioHarvest Sciences advances CDMO project with Nasdaq-listed pharmaceutical company to next stage

  • BioHarvest Announces Completion of Stage 1 Development for CDMO Contract with Nasdaq-Listed Pharmaceutical Company

  • Lifecore Biomedical to Participate at Upcoming CDMO Live 2025 Conference

  • WuXi Biologics Receives CDMO Leadership Awards for Eighth Consecutive Year

  • Scinai to Connect with Investors, Showcase its Innovative I&I pipeline and its Boutique cGMP Biologics CDMO during BIO-Europe Spring 2025

  • Humanetics Selects Lifecore Biomedical to Deliver CDMO Services Supporting Development of BIO 300 for the Prevention of Acute Radiation Syndrome

  • The Schall Law Firm Invites Shareholders With Losses In Avid Bioservices, Inc. To Join A Securities Fraud Investigation

  • An Investigation Has Been Launched Into Avid Bioservices, Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

  • The Schall Law Firm Invites Shareholders With Losses In Avid Bioservices, Inc. To Join A Securities Fraud Investigation

  • An Investigation Has Been Launched Into Avid Bioservices, Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

  • The Schall Law Firm Invites Shareholders With Losses In Avid Bioservices, Inc. To Join A Securities Fraud Investigation

  • Avid Bioservices, Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

  • The Schall Law Firm Invites Shareholders With Losses In Avid Bioservices, Inc. To Join A Securities Fraud Investigation

  • Avid Bioservices, Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm